STOCK TITAN

HUTCHMED (China) Limited American Depositary Shares - HCM STOCK NEWS

Welcome to our dedicated page for HUTCHMED (China) American Depositary Shares news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on HUTCHMED (China) American Depositary Shares stock.

HUTCHMED China Ltd, formerly known as Hutchison China Meditech Ltd, is a prominent player in the healthcare sector, focusing primarily on the manufacturing and sale of pharmaceuticals. The company is engaged in the development, production, and commercialization of therapies targeting oncology and immunological diseases. HUTCHMED operates through three main business segments: Innovation Platform, Commercial Platform, and Production.

Within the Innovation Platform, HUTCHMED dedicates extensive resources to research and development, aiming to discover novel drug candidates and advance them through clinical trials. The Commercial Platform includes the marketing and distribution aspects, where the company leverages its significant presence in China to bring its products to market. The Production segment focuses on the manufacturing of these drugs, following stringent quality standards.

HUTCHMED has achieved several milestones, including the development of its flagship products such as Savolitinib and Sulfatinib, which are undergoing various stages of clinical trials. Recent updates indicate promising subgroup efficacy and improved quality of life data, as presented at ASCO 2024. These advancements underline the company's commitment to addressing unmet medical needs and enhancing patient care.

Financially, HUTCHMED maintains a robust pipeline of projects and collaborations with global pharmaceutical giants, bolstering its position in the market. The company's strategic partnerships and alliances play a crucial role in expanding its research capabilities and accelerating drug development processes.

Overall, HUTCHMED China Ltd stands as a noteworthy entity in the pharmaceutical industry, continually striving to innovate and improve its product offerings to meet the growing healthcare demands in China and beyond.

Rhea-AI Summary
HUTCHMED (China) Limited (HCM) announces that ELUNATE® and SULANDA® will continue to be included in the National Reimbursement Drug List (NRDL) under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (NHSA). The updated NRDL will maintain the same terms as the current two-year agreement, allowing more patients in China to access these innovative medicines for the treatment of metastatic colorectal cancer and non-pancreatic and pancreatic neuroendocrine tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary
HUTCHMED (China) Limited (HCM) has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab for treating advanced renal cell carcinoma in China. The study aims to evaluate the efficacy and safety of the combination versus axitinib or everolimus monotherapy, with topline results expected by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
HUTCHMED (China) Limited (HCM) released new clinical data from ongoing studies with their investigational drug candidates fruquintinib, surufatinib, and HMPL-295. The data will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Congress and ESMO Immuno-Oncology Congress in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
Rhea-AI Summary
HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) announced that its partner Takeda received U.S. FDA approval for FRUZAQLA™ (fruquintinib), an oral targeted therapy for metastatic colorectal cancer, triggering a US$35 million milestone payment and royalties on net sales. The approval is a landmark moment for metastatic colorectal cancer patients in the U.S., with FRUZAQLA being the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated metastatic CRC regardless of biomarker status. The approval is based on data from two large Phase III trials, with consistent benefits among patients treated with FRUZAQLA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
-
Rhea-AI Summary
Takeda submits NDA for fruquintinib in Japan for metastatic colorectal cancer treatment, based on successful clinical trials
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary
HUTCHMED announces positive results from Phase IIIb trial of savolitinib in NSCLC patients with MET exon 14 skipping alterations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
Rhea-AI Summary
HUTCHMED completes patient enrollment of tazemetostat bridging study in China for the treatment of relapsed/refractory follicular lymphoma (R/R FL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary
HUTCHMED receives Breakthrough Therapy Designation for savolitinib in gastric cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.16%
Tags
none
-
Rhea-AI Summary
HUTCHMED's Phase III trial of sovleplenib meets primary and secondary endpoints in ITP patients in China, plans for regulatory submission underway
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
Rhea-AI Summary
HUTCHMED (China) Limited (HCM; 13) Reports 164% Revenue Growth, Net Income of US$169 million, and Strategic Progress in Global Partnership with Takeda
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none

FAQ

What is the current stock price of HUTCHMED (China) American Depositary Shares (HCM)?

The current stock price of HUTCHMED (China) American Depositary Shares (HCM) is $14.31 as of December 20, 2024.

What is the market cap of HUTCHMED (China) American Depositary Shares (HCM)?

The market cap of HUTCHMED (China) American Depositary Shares (HCM) is approximately 2.5B.

What does HUTCHMED China Ltd specialize in?

HUTCHMED China Ltd specializes in the development, production, and sale of pharmaceuticals, particularly targeting oncology and immunological diseases.

What are the key business segments of HUTCHMED?

HUTCHMED operates through three main business segments: Innovation Platform, Commercial Platform, and Production.

What are some of HUTCHMED's flagship products?

HUTCHMED's flagship products include Savolitinib and Sulfatinib, currently in various stages of clinical trials.

How does HUTCHMED contribute to the healthcare sector?

HUTCHMED contributes by developing innovative therapies for oncology and immunological diseases, enhancing patient care and addressing unmet medical needs.

What recent achievements has HUTCHMED made?

HUTCHMED recently presented promising subgroup efficacy and quality of life data at ASCO 2024.

What financial position does HUTCHMED hold?

HUTCHMED maintains a robust pipeline and collaborates with global pharmaceutical giants, strengthening its market position.

Who are HUTCHMED's partners?

HUTCHMED collaborates with several global pharmaceutical companies to enhance its research and development capabilities.

What is the focus of HUTCHMED's Innovation Platform?

The Innovation Platform focuses on discovering new drug candidates and advancing them through clinical trials.

How does HUTCHMED's Commercial Platform function?

The Commercial Platform involves the marketing and distribution of HUTCHMED's pharmaceutical products, primarily in China.

What standards does HUTCHMED's Production segment follow?

HUTCHMED's Production segment adheres to stringent quality standards to ensure the efficacy and safety of its drugs.

HUTCHMED (China) Limited American Depositary Shares

Nasdaq:HCM

HCM Rankings

HCM Stock Data

2.48B
174.10M
0.13%
4.29%
0.31%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hong Kong